The European MammoWave trial has begun at Cattinara Hospital. It involves the use of an innovative breast imaging technology based on non-ionising microwaves. The aim of the study is to assess the effectiveness of this new system for breast cancer screening.

The study is open to asymptomatic women in the screening age group (45–74 years) who have had a mammogram within the last 30 days or have one scheduled.

Participation is free and voluntary.

The examination is carried out at the Department of Diagnostic and Interventional Radiology at Cattinara Hospital, directed by Professor Maria Assunta Cova, in the clinic dedicated to the MammoWave study.

The centre is one of ten selected across Europe to take part in this international clinical trial, which will involve over 10,000 women in five countries.

What is MammoWave?

MammoWave is a medical device that uses very low-power microwaves to create a map of breast tissue, with no need for compression or contrast agents.

The examination is quick, safe and non-invasive.

Thanks to advanced software and artificial intelligence algorithms, the system can detect any abnormalities in the tissue, classifying them as either “suspicious” or “non-suspicious”.

A step forward in prevention

Taking part in this study means actively contributing to the development of new methods for early breast cancer detection – methods that are more accessible, safer and suitable for repeat use over time.

Where and how to take part

Participation includes:

• a brief eligibility interview
• the examination (approximately 15 minutes)
• no use of ionising radiation or breast compression.

Info:

Tel. 0403994862; mammowavetrieste@gmail.com